- Details
- At the 2024 LUGPA annual meeting, Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer, adjuvant pembrolizumab for high-risk renal cell carcinoma, and CA9 PET imaging for kidney cancer. He also shares survey data highlighting community urology's growin...
|
- Details
- Zachary Klaassen speaks with Pedro Barata about a publication examining transcription profiles in renal cell carcinoma. The discussion explores the evolution from DNA-based to RNA-based genomic analysis in RCC, focusing on their study of over 600 patients' gene expression signatures across different RCC subtypes. Dr. Barata emphasizes that non-clear cell RCC comprises biologically distinct cancers...
|
- Details
- Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in advanced urothelial cancer, which shows promising early results with a 40% response rate in previously treated patients. The conversation also explores NKT2152, a HIF2a inhibitor for renal cell carcinoma,...
|
- Details
- Laurence Albiges joins Zachary Klaassen to discuss the CheckMate 67T trial results. The phase 3 non-inferiority study compares subcutaneous versus intravenous administration of nivolumab in renal cell carcinoma patients who have failed prior VEGF-TKI therapy. The trial meets its co-primary pharmacokinetic endpoints, demonstrating non-inferiority of subcutaneous administration, while showing simila...
|
- Details
- Brian Rini joins Pedro Barata to discuss the updated results of the Phase 3 LITESPARK-005 trial. The study, which led to belzutifan's approval in December 2023, compares belzutifan to everolimus in refractory clear cell RCC patients who previously received PD-1/PD-L1 and VEGF-TKI therapy. While the trial demonstrates improved progression-free survival and response rates with belzutifan, overall su...
|
- Details
- Leslie Ballas interviews Chad Tang about the use of stereotactic body radiation therapy (SBRT) in metastatic renal cell carcinoma (RCC). Dr. Tang discusses two key approaches: treating oligometastatic disease (up to five metastatic sites) and oligoprogressive disease (one to three progressing sites). He presents data from recent studies showing SBRT's potential to delay the need for systemic thera...
|
- Details
- Sam Chang interviews Ignacio Duran about the highlights of ESMO 2024 in non-prostate genitourinary oncology. Dr. Duran discusses key findings in kidney and bladder cancer. For kidney cancer, he highlights studies challenging the sequencing of checkpoint inhibitors and new treatment options for non-clear cell carcinoma. In bladder cancer, Dr. Duran reviews three studies that could impact clinical p...
|
- Details
- Alicia Morgans interviews David Braun about novel serum glycoproteomic biomarkers in the CheckMate 9ER study for kidney cancer. Dr. Braun discusses the exploratory post-hoc analysis using the InterVenn GlycoVision Glycoproteomics platform to investigate potential prognostic and predictive biomarkers. He highlights findings that higher levels of glycosylation are associated with worse outcomes, reg...
|
- Details
- Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy. Results...
|
- Details
- Chiara Ciccarese discusses the TACITO-II trial results, evaluating fecal microbiota transplantation (FMT) in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. The phase II randomized study shows promising results, with FMT increasing the one-year progression-free survival rate from 35% to 66.7%. Dr. Ciccarese highlights the trial's novelty in demonstrating the tra...
|
